Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab randomized-withdrawal extension study in older adults with sarcopenia
2015-000471-27Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sarcopenia comparing Continued bimagrumab with Bimagrumab withdrawal to placebo (2 arms). Primary endpoint: 6-minute walk test. Started Sep 2015; status: completed.
02
Drugs
bimagrumab
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on 2015-000471-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000471-27.